trding,

Thanks for sharing. I think you nailed it, obviously Leronlimab has been superior to the other CCR5 antagonists in showing much less (to put it mildly) SAE's.

The reason might be very well what you have pointed out: inhibitors that do not block normal receptor activity (likely hindering their responsiveness accounts for some of the reported secondary effects with other drugs).

Honestly, I am not trained in medicine and my understanding falters at some stage when reading these papers; I get the overall picture but, something is for sure, there has been a lot of research in CCR5, the science behind it is solid and we have a potential blockbuster drug in our hands.

Let's hope the results keep being positive and the "sky is the limit" or "we will be the next Humira"; I am here paraphrasing NP on his honor.